Live Chat

CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 76,3% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Vir Biotechnology VIR

VirBiotechnology live grafieken

Inzichten

Weekly Search
Weekly
Daily
date Sluit change % verandering Openen Piek Bodem

Markets.com news

New Zealand dollar drops on unexpected dovish tone from RBNZ
Georgy Istigechev 2024 Jul 10, 10:00

Unexpected dovish tone from RBNZ drops New Zealand dollar

Forex Indices USD
Sterling steady as investors take in UK, French election results
Georgy Istigechev 2024 Jul 09, 10:15

Sterling steady near one-month high in wake of UK election

Forex Indices GBP USD EUR
BP shares fall on Q2 profit warning
Georgy Istigechev 2024 Jul 09, 10:00

BP shares drop over 4% on Q2 lower profit warning

Shares Indices Oil FTSE100
BP shares dip ahead of Powell Congress testimony
Neil Wilson 2024 Jul 09, 07:30

BP dips, Powell Congress speech ahead, records for Tokyo, NY

Shares Indices Forex Commodities

Info

Spread

0.05

Spread (%)

0.6623 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Dinsdag

14:31 - 20:59

Maandag

14:31-20:59

Woensdag

14:31-20:59

Donderdag

14:31-20:59

Vrijdag

14:31-20:59

Inkomstenverklaring

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

1010864832

Uitstaande aandelen

137720000

Datum winstcijfer (volgende)

0000-00-00

instr__dividend_date

instr__ex_dividend_date

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

Winst per aandeel

-3.93

Uitstaande aandelen

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Meer informatie over dit instrument

Activa
Verkoop
Koop
% verandering
Gerelateerde instrumenten
Trustpilot
Live Chat